There are significant differences in innovation performance between countries. Additionally, the pharmaceutical sector is stronger in some countries than in others. This suggests that the development of the pharmaceutical industry can influence a country's innovation performance. Using the Global Innovation Index and selected performance measures of the pharmaceutical sector, this study examines how the pharmaceutical sector influences the innovation performance of countries from the European context. The dataset of 27 European countries was analysed using simple, and multiple linear regressions and Pearson correlation. Our findings show that only three indicators of the pharmaceutical industry, more precisely pharmaceutical Research and Development, pharmaceutical exports, and pharmaceutical employment explain the innovation performance of a country largely. Pharmaceutical Research and Development and exports have a significant positive impact on a country's innovation performance, whereas employment in the pharmaceutical industry has a slightly negative impact. Additionally, global innovation performance has been found to positively influence life expectancy. We further outline t
Data scarcity in pharmaceutical research has led to reliance on labour-intensive trial-and-error approaches for development rather than data-driven methods. While Machine Learning offers a solution, existing datasets are often small and noisy, limiting their utility. To address this, we developed a Variationally Encoded Conditional Tabular Generative Adversarial Network (VECT-GAN), a novel generative model specifically designed for augmenting small, noisy datasets. We introduce a pipeline where data is augmented before regression model development and demonstrate that this consistently and significantly improves performance over other state-of-the-art tabular generative models. We apply this pipeline across six pharmaceutical datasets, and highlight its real-world applicability by developing novel polymers with medically desirable mucoadhesive properties, which we made and experimentally characterised. Additionally, we pre-train the model on the ChEMBL database of drug-like molecules, leveraging knowledge distillation to enhance its generalisability, making it readily available for use on pharmaceutical datasets containing small molecules, an extremely common pharmaceutical task. W
Pharmaceutical supply chains (PSCs) struggle with inventory management (IM) due to unpredictable demand patterns and variable lead times associated with restocking. This complexity is further compounded by the finite shelf lives of pharmaceutical products, which necessitate a delicate balance between adequate stock and minimal waste. These intertwined factors create a complex optimization problem that requires sophisticated inventory strategies to ensure both product availability and PSC efficiency. This study aims to develop an optimal inventory replenishment policy for pharmaceutical products that can handle the stochasticity arising from uncertain demand and variable PSC conditions. The objective is to maximize the profitability of the PSC while maintaining a high patient service level. We formulate the problem as a Markov decision process and propose a deep reinforcement learning (DRL) approach, specifically, a hybrid asynchronous advantage actor critic distributed proximal policy optimization (A3C DPPO)algorithm. The A3C DPPO algorithm is tailored to handle the continuous action space inherent in IM. The numerical results demonstrate that the proposed algorithm adaptively upda
The pharmaceutical supply chain faces escalating cybersecurity challenges threatening patient safety and operational continuity. This paper examines the transformative potential of zero trust architecture for enhancing security and resilience within this critical ecosystem. We explore the challenges posed by data breaches, counterfeiting, and disruptions and introduce the principles of continuous verification, least-privilege access, and data-centric security inherent in zero trust. Real-world case studies illustrate successful implementations. Benefits include heightened security, data protection, and adaptable resilience. As recognized by researchers and industrialists, a reliable drug tracing system is crucial for ensuring drug safety throughout the pharmaceutical production process. One of the most pivotal domains within the pharmaceutical industry and its associated supply chains where zero trust can be effectively implemented is in the management of narcotics, high-health-risk drugs, and abusable substances. By embracing zero trust, the pharmaceutical industry fortifies its supply chain against constantly changing cyber threats, ensuring the trustworthiness of critical medica
Pharmaceutical research and development has accumulated vast and heterogeneous archives of data. Much of this knowledge stems from discontinued programs, and reusing these archives is invaluable for reverse translation. However, in practice, such reuse is often infeasible. In this work, we introduce DiscoVerse, a multi-agent co-scientist designed to support pharmaceutical research and development at Roche. Designed as a human-in-the-loop assistant, DiscoVerse enables domain-specific queries by delivering evidence-based answers: it retrieves relevant data, links across documents, summarises key findings and preserves institutional memory. We assess DiscoVerse through expert evaluation of source-linked outputs. Our evaluation spans a selected subset of 180 molecules from Roche's research and development repositories, encompassing over 0.87 billion BPE tokens and more than four decades of research. To our knowledge, this represents the first agentic framework to be systematically assessed on real pharmaceutical data for reverse translation, enabled by authorized access to confidential archives covering the full lifecycle of drug development. Our contributions include: role-specialized
We present a Japanese domain-specific language model for the pharmaceutical field, developed through continual pretraining on 2 billion Japanese pharmaceutical tokens and 8 billion English biomedical tokens. To enable rigorous evaluation, we introduce three new benchmarks: YakugakuQA, based on national pharmacist licensing exams; NayoseQA, which tests cross-lingual synonym and terminology normalization; and SogoCheck, a novel task designed to assess consistency reasoning between paired statements. We evaluate our model against both open-source medical LLMs and commercial models, including GPT-4o. Results show that our domain-specific model outperforms existing open models and achieves competitive performance with commercial ones, particularly on terminology-heavy and knowledge-based tasks. Interestingly, even GPT-4o performs poorly on SogoCheck, suggesting that cross-sentence consistency reasoning remains an open challenge. Our benchmark suite offers a broader diagnostic lens for pharmaceutical NLP, covering factual recall, lexical variation, and logical consistency. This work demonstrates the feasibility of building practical, secure, and cost-effective language models for Japanes
Research and Development is the largest budget position in the pharmaceutical industry, with clinical trials being a critical, yet costly and time-consuming component to inform decisions. Beyond drug efficacy, the probability of success and efficiency of research and development are highly dependent on the approaches used for designing, analyzing, and interpreting clinical trials. Deep understanding of statistical methodology and quantitative approaches is therefore essential. Consequently, dedicated methodology groups have emerged in mid-size and large pharmaceutical companies and CROs. Their remit is to lead the conception and implementation of innovative quantitative methodologies in order to improve drug development, often by addressing complexities or offering more efficient designs. To achieve this, they collaborate internally and externally (e.g., with academics, regulators) to identify common challenges and tear down silos in order to invest in methods with the highest impact on efficiency and value to the portfolio. Given the immense financial stakes of drug development -- where delays carry massive implications -- these groups represent a critical strategic investment. Ho
The survival of unorganized pharmacies is increasingly challenging in the face of growing competition from organized and e-pharmaceutical retail channels in emerging economies. A theoretical model is developed to capture the triple-channel interactions among unorganized, organized and e-retailing in emerging markets, taking into account the essential features of the pharmaceutical retail landscape, consumers, retailers and pharmaceutical products. Given the retailer and customer-specific factors, the price-setting game between the triple-channel retailers yielded the optimal prices for these retailers. The analysis found that the product category level demand has no influence on optimal pricing strategies of the retailers. The analysis also reveals counterintuitive results, for instance, (i) an increase in customer acceptance of unorganized retailers will result in a decrease in profits of both unorganized and organized retailers; (ii) as the distance and transportation cost to unorganized retailers increases for the consumers, the profit of the unorganized retailer increases; and (iii) consumers marginal utility of money has no influence on the optimal price, but have an influence
Controlling the size of powder particles is pivotal in the design of many pharmaceutical forms and the related manufacturing processes and plants. One of the most common techniques for particle size reduction in process industry is powder milling, whose efficiency relates to the mechanical properties of powder particles themselves. In this work, we first characterize the elastic and plastic response of different pharmaceutical powders by measuring their Young modulus, the hardness and the brittleness index via nano-indentation. Subsequently, we analyze the behavior of those powder samples during comminution via jet-mill at different process conditions. Finally, the correlation between single particle mechanical properties and milling process results is illustrated; the possibility to build a predictive model for powder grindability, based on nano-indentation data, is critically discussed
Pharmaceutical patents play an important role by protecting the innovation from copies but also drive researchers to innovate, create new products, and promote disruptive innovations focusing on collective health. The study of patent management usually refers to an exhaustive manual search. This happens, because patent documents are complex with a lot of details regarding the claims and methodology/results explanation of the invention. To mitigate the manual search, we proposed PATopics, a framework specially designed to extract relevant information for Pharmaceutical patents. PATopics is composed of four building blocks that extract textual information from the patents, build relevant topics that are capable of summarizing the patents, correlate these topics with useful patent characteristics and then, summarize the information in a friendly web interface to final users. The general contributions of PATopics are its ability to centralize patents and to manage patents into groups based on their similarities. We extensively analyzed the framework using 4,832 pharmaceutical patents concerning 809 molecules patented by 478 companies. In our analysis, we evaluate the use of the framewo
This document offers a critical overview of the emerging trends and significant advancements in artificial intelligence (AI) within the pharmaceutical industry. Detailing its application across key operational areas, including research and development, animal testing, clinical trials, hospital clinical stages, production, regulatory affairs, quality control and other supporting areas, the paper categorically examines AI's role in each sector. Special emphasis is placed on cutting-edge AI technologies like machine learning algorithms and their contributions to various aspects of pharmaceutical operations. Through this comprehensive analysis, the paper highlights the transformative potential of AI in reshaping the pharmaceutical industry's future.
Pharmaceutical patents play a vital role in biochemical industries, especially in drug discovery, providing researchers with unique early access to data, experimental results, and research insights. With the advancement of machine learning, patent analysis has evolved from manual labor to tasks assisted by automatic tools. However, there still lacks an unified agent that assists every aspect of patent analysis, from patent reading to core chemical identification. Leveraging the capabilities of Large Language Models (LLMs) to understand requests and follow instructions, we introduce the $\textbf{first}$ intelligent agent in this domain, $\texttt{PatentAgent}$, poised to advance and potentially revolutionize the landscape of pharmaceutical research. $\texttt{PatentAgent}$ comprises three key end-to-end modules -- $\textit{PA-QA}$, $\textit{PA-Img2Mol}$, and $\textit{PA-CoreId}$ -- that respectively perform (1) patent question-answering, (2) image-to-molecular-structure conversion, and (3) core chemical structure identification, addressing the essential needs of scientists and practitioners in pharmaceutical patent analysis. Each module of $\texttt{PatentAgent}$ demonstrates significa
Many drugs have been withdrawn from the market worldwide, at a cost of billions of dollars, because of patient fatalities due to them unexpectedly disturbing heart rhythm. Even drugs for ailments as mild as hay fever have been withdrawn due to an unacceptable increase in risk of these heart rhythm disturbances. Consequently, the whole pharmaceutical industry expends a huge effort in checking all new drugs for any unwanted side effects on the heart. The predominant root cause has been identified as drug molecules blocking ionic current flows in the heart. Block of individual types of ionic currents can now be measured experimentally at an early stage of drug development, and this is the standard screening approach for a number of ion currents in many large pharmaceutical companies. However, clinical risk is a complex function of the degree of block of many different types of cardiac ion currents, and this is difficult to understand by looking at results of these screens independently. By using ordinary differential equation models for the electrical activity of heart cells (electrophysiology models) we can integrate information from different types of currents, to predict the effect
The digital transformation of pharmaceutical industry is a challenging task due to the high complexity of involved elements and the strict regulatory compliance. Maintenance activities in the pharmaceutical industry play an essential role in ensuring product quality and integral functioning of equipment and premises. This paper first identifies the key challenges of digitalization in pharmaceutical industry and creates the corresponding problem space for key involved elements. A literature review is conducted to investigate the mainstream maintenance strategies, digitalization models, tools and official guidance from authorities in pharmaceutical industry. Based on the review result, a semantic-driven digitalization framework is proposed aiming to improve the digital continuity and cohesion of digital resources and technologies for maintenance activities in the pharmaceutical industry. A case study is conducted to verify the feasibility of the proposed framework based on the water sampling activities in Merck Serono facility in Switzerland. A tool-chain is presented to enable the functional modules of the framework. Some of the key functional modules within the framework are implem
A stability chamber is essential for pharmaceutical facilities to test the stability and quality of products over time by exposing them to different environmental conditions. This paper introduces an IoT-enabled stability chamber designed for the pharmaceutical industry. We constructed four stability chambers by leveraging the existing infrastructure within a manufacturing facility. Each chamber is controlled using a state-of-the-art Proportional Integral Derivative (PID) system based on the Siemens S7-1200 PLC. The Siemens WinCC Runtime Advanced platform, compliant with FDA 21 CFR Part 11, was used for visualizing chamber data. Additionally, an Internet of Things (IoT) application was developed to remotely monitor sensor data through any client application. This research aims to enhance the performance of traditional stability chambers by integrating IoT functionalities, making them more cost-effective and user-friendly.
The pharmaceutical manufacturing faces critical challenges due to the global threat of counterfeit drugs. This paper proposes a new approach of protected QR codes to secure unique product information for safeguarding the pharmaceutical supply chain. The proposed solution integrates secure QR code generation and encrypted data transmission to establish a comprehensive anti-counterfeit ecosystem. The protected QR codes encapsulate product information that cannot be identified using traditional QR code scanners which protect the information against replication and tampering. The system is developed with scalability in mind, which can be easily implemented without introducing any additional modification in the traditional supply chain.
The advent of 3D printing has transformed the pharmaceutical industry, enabling precision drug manufacturing with controlled release profiles, dosing, and structural complexity. Additive manufacturing (AM) addresses the growing demand for personalized medicine, overcoming limitations of traditional methods. This technology facilitates tailored dosage forms, complex geometries, and real-time quality control. Recent advancements in drop-on-demand printing, UV curable inks, material science, and regulatory frameworks are discussed. Despite opportunities for cost reduction, flexibility, and decentralized manufacturing, challenges persist in scalability, reproducibility, and regulatory adaptation. This review provides an in-depth analysis of the current state of AM in pharmaceutical manufacturing, exploring recent developments, challenges, and future directions for mainstream integration.
In materials and pharmaceutical development, rapidly and accurately determining the similarity between X-ray powder diffraction (XRPD) measurements is crucial for efficient solid form screening and analysis. We present SMolNet, a classifier based on a Siamese network architecture, designed to automate the comparison of XRPD patterns. Our results show that training SMolNet on loss functions from the self-supervised learning domain yields a substantial boost in performance with respect to class separability and precision, specifically when classifying phases of previously unseen compounds. The application of SMolNet demonstrates significant improvements in screening efficiency across multiple active pharmaceutical ingredients, providing a powerful tool for scientists to discover and categorize measurements with reliable accuracy.
Pharmaceutical analysis, as the core curriculum of chemistry, chemical engineering and pharmaceutical engineering, contains broad and in-depth knowledge that leads to massive learning & teaching loads. There are more than 100 analytical methods of medicines in this course. As such, this subject is a big challenge for both students and lecturers. A novel chemical structure teaching (CST) method was developed based on our long-term teaching experience to cope with these challenges. It has been shown in practice that this CST method can significantly unload the stress of students and lecturers simultaneously. The survey about the improvement of students' interests was carried out and listed in the form of questionnaire. The outcome of CST also indicates that it can help them to form abilities of critical and logical thinking as independent learners, motivate them to discuss with their peers and lecturers, and eventually improve average grades. Furthermore, CST can be beneficial for lecturers who instruct other relevant curriculum in chemical or pharmaceutical engineering to improve the teaching outcome, such as organic chemistry, spectrum analysis, pharmaceutical synthesis and med
Various non pharmaceutical interventions have been settled to minimise the burden of the COVID-19 outbreak. We build a framework to analyse the dynamics of non pharmaceutical interventions, to distinguish between mitigations measures leading to objective scientific improvements and mitigations based on both political and scientific considerations. We analyse two possible strategies within this framework. Namely, we consider mitigations driven by the limited resources of the health system and mitigations where a constant set of measures is applied at different moments. We describe the optimal interventions for these scenarios. Our approach is mathematical and involves sir differential systems, it is qualitative and geometrical rather than computational. Along with the analysis of these scenarios, we collect several results that may be useful on their own, in particular on the ground when the variables are not known in real time.